247 related articles for article (PubMed ID: 30967424)
1. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA
Haller MJ; Long SA; Blanchfield JL; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Geyer SM; Warnock MV; Miller JL; Atkinson MA; Becker DJ; Baidal DA; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell WE; Wilson DM; Greenbaum CJ;
Diabetes; 2019 Jun; 68(6):1267-1276. PubMed ID: 30967424
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA
Haller MJ; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Miller JL; Atkinson MA; Becker DJ; Baidal D; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell W; Wilson DM; Greenbaum CJ;
Diabetes Care; 2018 Sep; 41(9):1917-1925. PubMed ID: 30012675
[TBL] [Abstract][Full Text] [Related]
3. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Perry DJ; Schultz AR; Hulme MA; Shuster JJ; Zou B; Wasserfall CH; Posgai AL; Mathews CE; Brusko TM; Atkinson MA; Schatz DA
Diabetes; 2016 Dec; 65(12):3765-3775. PubMed ID: 27669730
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.
Lin A; Mack JA; Bruggeman B; Jacobsen LM; Posgai AL; Wasserfall CH; Brusko TM; Atkinson MA; Gitelman SE; Gottlieb PA; Gurka MJ; Mathews CE; Schatz DA; Haller MJ
Diabetes; 2021 May; 70(5):1123-1129. PubMed ID: 33632742
[TBL] [Abstract][Full Text] [Related]
5. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Rosenthal SM; Shuster JJ; Zou B; Brusko TM; Hulme MA; Wasserfall CH; Mathews CE; Atkinson MA; Schatz DA
J Clin Invest; 2015 Jan; 125(1):448-55. PubMed ID: 25500887
[TBL] [Abstract][Full Text] [Related]
6. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Gitelman SE; Gottlieb PA; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Harris KM; Kanaparthi S; Phippard D; Ding L; Bluestone JA; Ehlers MR;
Diabetologia; 2016 Jun; 59(6):1153-61. PubMed ID: 27053235
[TBL] [Abstract][Full Text] [Related]
7. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE; Gottlieb PA; Rigby MR; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; Ding L; Bluestone JA; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):306-16. PubMed ID: 24622416
[TBL] [Abstract][Full Text] [Related]
8. Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes.
Jacobsen LM; Diggins K; Blanchfield L; McNichols J; Perry DJ; Brant J; Dong X; Bacher R; Gersuk VH; Schatz DA; Atkinson MA; Mathews CE; Haller MJ; Long SA; Linsley PS; Brusko TM
JCI Insight; 2023 Aug; 8(16):. PubMed ID: 37432736
[TBL] [Abstract][Full Text] [Related]
9. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Wilhelm-Benartzi CS; Miller SE; Bruggraber S; Picton D; Wilson M; Gatley K; Chhabra A; Marcovecchio ML; Hendriks AEJ; Morobé H; Chmura PJ; Bond S; Aschemeier-Fuchs B; Knip M; Tree T; Overbergh L; Pall J; Arnaud O; Haller MJ; Nitsche A; Schulte AM; Mathieu C; Mander A; Dunger D
BMJ Open; 2021 Dec; 11(12):e053669. PubMed ID: 34876434
[TBL] [Abstract][Full Text] [Related]
10. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
Parker MJ; Xue S; Alexander JJ; Wasserfall CH; Campbell-Thompson ML; Battaglia M; Gregori S; Mathews CE; Song S; Troutt M; Eisenbeis S; Williams J; Schatz DA; Haller MJ; Atkinson MA
Diabetes; 2009 Oct; 58(10):2277-84. PubMed ID: 19628781
[TBL] [Abstract][Full Text] [Related]
11. Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.
Haller MJ; Atkinson MA; Wasserfall CH; Brusko TM; Mathews CE; Hulme M; Cintron M; Shuster J; McGrail K; Posgai A; Schatz D
Clin Exp Immunol; 2016 Mar; 183(3):350-7. PubMed ID: 26462724
[TBL] [Abstract][Full Text] [Related]
12. Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes.
Gaglia JL; Daley HL; Bryant NK; Ritz J; Dong T; Skyler JS; Jiang H
NEJM Evid; 2024 Jul; 3(7):EVIDoa2300238. PubMed ID: 38916421
[TBL] [Abstract][Full Text] [Related]
13. Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
Pinckney A; Rigby MR; Keyes-Elstein L; Soppe CL; Nepom GT; Ehlers MR
Clin Ther; 2016 Jun; 38(6):1327-1339. PubMed ID: 27209482
[TBL] [Abstract][Full Text] [Related]
14. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
15. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.
Foster TP; Jacobsen LM; Bruggeman B; Salmon C; Hosford J; Chen A; Cintron M; Mathews CE; Wasserfall C; Brusko MA; Brusko TM; Atkinson MA; Schatz DA; Haller MJ
Diabetes Care; 2024 Feb; 47(2):285-289. PubMed ID: 38117469
[TBL] [Abstract][Full Text] [Related]
17. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR; DiMeglio LA; Rendell MS; Felner EI; Dostou JM; Gitelman SE; Patel CM; Griffin KJ; Tsalikian E; Gottlieb PA; Greenbaum CJ; Sherry NA; Moore WV; Monzavi R; Willi SM; Raskin P; Moran A; Russell WE; Pinckney A; Keyes-Elstein L; Howell M; Aggarwal S; Lim N; Phippard D; Nepom GT; McNamara J; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):284-94. PubMed ID: 24622414
[TBL] [Abstract][Full Text] [Related]
18. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
Hagopian W; Ferry RJ; Sherry N; Carlin D; Bonvini E; Johnson S; Stein KE; Koenig S; Daifotis AG; Herold KC; Ludvigsson J;
Diabetes; 2013 Nov; 62(11):3901-8. PubMed ID: 23801579
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory effect of anti-thymocyte globulin monotherapy on peripheral lymphoid tissues of non-obese diabetic mice.
Vargova L; Zacharovova K; Dovolilova E; Vojtova L; Saudek F
Transplant Proc; 2011 Nov; 43(9):3277-80. PubMed ID: 22099776
[TBL] [Abstract][Full Text] [Related]
20. Combined intervention for the tertiary prevention of type 1 diabetes.
Kawasaki E
J Diabetes Investig; 2016 May; 7(3):300-2. PubMed ID: 27330714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
